Veradermics, Incorporated (MANE) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−39.5x

Market Cap

$4.12B

MomentumView details →

1D Return

+0.78%

YTD Return

—

RSI (14)

41.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−39.5x

Market Cap

$4.12B

RSI (14)

41.9

MomentumView details →

1D Return

+0.78%

YTD Return

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−9.62%

ROA (TTM)

−9.48%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−$0.58

EPS Surprise

10.43%

Beats (12Q)

1/12

Next Q EPS Est

−$0.61

Avg Surprise (4Q)

10.43%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

70.53x

Quick Ratio

70.53x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−78.24M

Op. CF (TTM)

−62.92M

Next earningsNov 10, 2026 →

Latest newsMore news →

Veradermics reported its financial results for the second quarter ended June 30, 2026.24d ago

Veradermics Incorporated released topline results from an open-label Phase 2 trial of its experimental oral hair loss drug VDPHL01 in women with mild-to-moderate pattern hair loss.51d ago

Similar companies

Viking Therapeutics, Inc.VKTX Relay Therapeutics, Inc.RLAY Legend Biotech CorporationLEGN Telix Pharmaceuticals LimitedTLX TransThera Sciences (Nanjing) Inc.02617.HK 华恒生物688639.SH Find similar companies →

Latest newsMore news →

Veradermics reported its financial results for the second quarter ended June 30, 2026.24d ago Veradermics Incorporated released topline results from an open-label Phase 2 trial of its experimental oral hair loss drug VDPHL01 in women with mild-to-moderate pattern hair loss.51d ago